Form 4: Semler Scientific Director Acquires Stock Options

Semler Scientific Director Eric Semler acquired 4,000 stock options exercisable at $17.78 per share, effective January 2, 2026.

Summary

• Eric Semler, a Director at Semler Scientific, Inc. (SMLR), acquired 4,000 stock options.
• The options have an exercise price of $17.78 per share.
• The transaction date and exercisable date for these options is January 2, 2026.
• The options are set to expire on January 2, 2036.
• Following this transaction, Eric Semler directly beneficially owns 4,000 derivative securities.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director can be seen as a moderately positive signal, indicating management's belief in future stock price appreciation. However, it's a standard compensation mechanism and not a direct cash investment.

Positives

• A director acquiring stock options can signal confidence in the company's future performance, as the options become more valuable if the stock price rises above the exercise price of $17.78.

Risks

• The value of the stock options is dependent on the future market price of Semler Scientific's common stock. If the stock price does not exceed the exercise price of $17.78, the options may expire worthless.

Future Outlook

This filing reports a scheduled insider transaction and does not contain explicit forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This is an insider transaction report, which is company-specific and does not directly relate to broader industry trends. However, insider equity grants can be a general indicator of sentiment within the company's leadership.

Comparison to Industry Standards

• This Form 4 filing is a standard report for an insider equity transaction. There are no specific operational or financial results to compare against industry benchmarks or comparable companies within the medical device or healthcare technology sector based solely on this filing.

Related Party Transactions

• The transaction involves Eric Semler, a Director of Semler Scientific, Inc., making it a related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grant of options could potentially dilute existing shareholders if exercised, but also aligns the director's interests with shareholder value creation by incentivizing stock price appreciation.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Monitor Semler Scientific's stock performance relative to the $17.78 exercise price.
• Observe future Form 4 filings for additional insider transactions or changes in beneficial ownership.

Key Dates

Keywords

Semler Scientific, SMLR, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant